Calliditas Therapeutics AB
NASDAQ:CALT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Calliditas Therapeutics AB (CALT) under the Base Case is USD per share.
Compared with the current market price of 40.0001 USD, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 4 years.
Create a free account · No card needed
Fundamental Analysis
What Calliditas Therapeutics AB Does
Calliditas Therapeutics AB, a biopharmaceutical company based in Sweden, has carved a niche for itself in the realm of specialty pharmaceuticals, particularly focusing on rare diseases. The company stands out with its dedication to developing novel treatments for orphan conditions that traditionally go under-addressed by larger pharmaceutical entities. Pivotal to its identity, Calliditas leverages its expertise in renal and hepatic diseases, emphasizing precision medicine aimed at improving the lives of patients with severe unmet medical conditions.
- Headquarters
- Sweden SE
- Employees
- 65
- IPO date
- Jun 29, 2018
Balance Sheet
Continue CALT Research
Decided on Calliditas Therapeutics? Get an email when CALT reaches the price you’d buy at. Free with an account.
What is the Intrinsic Value of one CALT stock?
The intrinsic value for
Calliditas Therapeutics AB (CALT) under the Base Case is USD.
Is CALT stock undervalued or overvalued?
Compared with the current market price of 40.0001 USD, the stock appears .